Journal of Computer-Aided Molecular Design

, Volume 32, Issue 1, pp 21–44 | Cite as

Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2

  • Christina Athanasiou
  • Sofia Vasilakaki
  • Dimitris Dellis
  • Zoe Cournia
Article

Abstract

Computer-aided drug design has become an integral part of drug discovery and development in the pharmaceutical and biotechnology industry, and is nowadays extensively used in the lead identification and lead optimization phases. The drug design data resource (D3R) organizes challenges against blinded experimental data to prospectively test computational methodologies as an opportunity for improved methods and algorithms to emerge. We participated in Grand Challenge 2 to predict the crystallographic poses of 36 Farnesoid X Receptor (FXR)-bound ligands and the relative binding affinities for two designated subsets of 18 and 15 FXR-bound ligands. Here, we present our methodology for pose and affinity predictions and its evaluation after the release of the experimental data. For predicting the crystallographic poses, we used docking and physics-based pose prediction methods guided by the binding poses of native ligands. For FXR ligands with known chemotypes in the PDB, we accurately predicted their binding modes, while for those with unknown chemotypes the predictions were more challenging. Our group ranked #1st (based on the median RMSD) out of 46 groups, which submitted complete entries for the binding pose prediction challenge. For the relative binding affinity prediction challenge, we performed free energy perturbation (FEP) calculations coupled with molecular dynamics (MD) simulations. FEP/MD calculations displayed a high success rate in identifying compounds with better or worse binding affinity than the reference (parent) compound. Our studies suggest that when ligands with chemical precedent are available in the literature, binding pose predictions using docking and physics-based methods are reliable; however, predictions are challenging for ligands with completely unknown chemotypes. We also show that FEP/MD calculations hold predictive value and can nowadays be used in a high throughput mode in a lead optimization project provided that crystal structures of sufficiently high quality are available.

Keywords

Free energy perturbation Docking Farnesoid X receptor FXR D3R FEP+ Drug design data resource 

Notes

Acknowledgements

The research leading to these results has been co-funded by the European Commission under the H2020 Research Infrastructures Contract No. 675121 (project VI-SEEM). Computational time was granted from the VI-SEEM project and the Greek National HPC facility—ARIS under the project ID “D3R”. Schrödinger representatives are acknowledged for their technical support. All data is available to download at: http://hdl.handle.net/21.15102/VISEEM-277

Supplementary material

10822_2017_75_MOESM1_ESM.pdf (35.4 mb)
Supplementary material 1 (PDF 36257 KB)

References

  1. 1.
    Baggett AW et al (2012) Structural characterization and computer-aided optimization of a small-molecule inhibitor of the Arp2/3 complex, a key regulator of the actin cytoskeleton. ChemMedChem 7(7):1286–1294CrossRefGoogle Scholar
  2. 2.
    Gkeka P et al (2013) Free energy calculations reveal the origin of binding preference for aminoadamantane blockers of influenza A/M2TM pore. J Chem Theory Comput 9(2):1272–1281CrossRefGoogle Scholar
  3. 3.
    Lionta E et al (2014) Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem 14(16):1923–1938CrossRefGoogle Scholar
  4. 4.
    Gathiaka S et al (2016) D3R grand challenge 2015: evaluation of protein-ligand pose and affinity predictions. J Comput Aided Mol Des 30(9):651–668CrossRefGoogle Scholar
  5. 5.
    Mey ASJS et al (2016) Blinded predictions of binding modes and energies of HSP90-α ligands for the 2015 D3R grand challenge. Bioorg Med Chem 24(20):4890–4899CrossRefGoogle Scholar
  6. 6.
    Misini Ignjatovic M et al (2016) Binding-affinity predictions of HSP90 in the D3R Grand Challenge 2015 with docking, MM/GBSA, QM/MM, and free-energy simulations. J Comput Aided Mol Des 30(9):707–730CrossRefGoogle Scholar
  7. 7.
    Damm KL, Carlson HA (2007) Exploring experimental sources of multiple protein conformations in structure-based drug design. J Am Chem Soc 129(26):8225–8235CrossRefGoogle Scholar
  8. 8.
    Knegtel RM, Kuntz ID, Oshiro CM (1997) Molecular docking to ensembles of protein structures. J Mol Biol 266(2):424–440CrossRefGoogle Scholar
  9. 9.
    Totrov M, Abagyan R (2008) Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr Opin Struct Biol 18(2):178–184CrossRefGoogle Scholar
  10. 10.
    Paul SM et al (2010) How to improve R&D productivity: the pharmaceutical industry’s Grand Challenge. Nat Rev Drug Discov 9(3):203–214Google Scholar
  11. 11.
    Wang L et al (2015) Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. J Am Chem Soc 137(7):2695–2703CrossRefGoogle Scholar
  12. 12.
    Christ CD (2016) Binding affinity prediction from molecular simulations: a new standard method in structure-based drug design? Available from https://f1000research.com/slides/5-1761
  13. 13.
    Christ CD, Fox T (2014) Accuracy assessment and automation of free energy calculations for drug design. J Chem Inf Model 54(1):108–120CrossRefGoogle Scholar
  14. 14.
    Lovering F et al (2016) Imidazotriazines: spleen tyrosine kinase (Syk) inhibitors identified by free-energy perturbation (FEP). ChemMedChem 11(2):217–233CrossRefGoogle Scholar
  15. 15.
    van Vlijmen H, Desjarlais RL, Mirzadegan T (2017) Computational chemistry at Janssen. J Comput Aided Mol Des 31(3):267–273CrossRefGoogle Scholar
  16. 16.
    Akwabi-Ameyaw A et al (2009) FXR agonist activity of conformationally constrained analogs of GW 4064. Bioorg Med Chem Lett 19(16):4733–4739CrossRefGoogle Scholar
  17. 17.
    Akwabi-Ameyaw A et al (2011) Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene. Bioorg Med Chem Lett 21(20):6154–6160CrossRefGoogle Scholar
  18. 18.
    Bass JY et al (2009) Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064. Bioorg Med Chem Lett 19(11):2969–2973CrossRefGoogle Scholar
  19. 19.
    Downes M et al (2003) A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 11(4):1079–1092CrossRefGoogle Scholar
  20. 20.
    Feng S et al (2009) Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorg Med Chem Lett 19(9):2595–2598CrossRefGoogle Scholar
  21. 21.
    Flatt B et al (2009) Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem 52(4):904–907CrossRefGoogle Scholar
  22. 22.
    Jin L et al (2013) The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun 4:1937Google Scholar
  23. 23.
    Lundquist JT et al (2010) Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. J Med Chem 53(4):1774–1787CrossRefGoogle Scholar
  24. 24.
    Mi LZ et al (2003) Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell 11(4):1093–1100CrossRefGoogle Scholar
  25. 25.
    Richter HG et al (2011) Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. Bioorg Med Chem Lett 21(4):1134–1140CrossRefGoogle Scholar
  26. 26.
    Richter HG et al (2011) Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia and diabetes. Bioorg Med Chem Lett 21(1):191–194CrossRefGoogle Scholar
  27. 27.
    Soisson SM et al (2008) Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc Natl Acad Sci USA 105(14):5337–5342CrossRefGoogle Scholar
  28. 28.
    Xu X et al (2015) Structural basis for small molecule NDB (N-benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino) benzamide) as a selective antagonist of farnesoid X receptor alpha (FXRalpha) in stabilizing the homodimerization of the receptor. J Biol Chem 290(32):19888–19899CrossRefGoogle Scholar
  29. 29.
    Dang LX, Merz KM, Kollman PA (1989) Free energy calculations on protein stability: Thr-157 .fwdarw. Val-157 mutation of T4 lysozyme. J Am Chem Soc 111(22):8505–8508CrossRefGoogle Scholar
  30. 30.
    Jorgensen WL (1989) Free energy calculations: a breakthrough for modeling organic chemistry in solution. Acc Chem Res 22(5):184–189CrossRefGoogle Scholar
  31. 31.
    Jorgensen WL (2009) Efficient drug lead discovery and optimization. Acc Chem Res 42(6):724–733CrossRefGoogle Scholar
  32. 32.
    Jorgensen WL, Ravimohan C (1985) Monte Carlo simulation of differences in free energies of hydration. J Chem Phys 83(6):3050–3054CrossRefGoogle Scholar
  33. 33.
    Jorgensen WL, Thomas LL (2008) Perspective on free-energy perturbation calculations for chemical equilibria. J Chem Theory Comput 4(6):869–876CrossRefGoogle Scholar
  34. 34.
    Kollman P (1993) Free energy calculations: applications to chemical and biochemical phenomena. Chem Rev 93(7):2395–2417CrossRefGoogle Scholar
  35. 35.
    Kollman PA, Merz KM (1990) Computer modeling of the interactions of complex molecules. Acc Chem Res 23(8):246–252CrossRefGoogle Scholar
  36. 36.
    Merz KM, Kollman PA (1989) Free energy perturbation simulations of the inhibition of thermolysin: prediction of the free energy of binding of a new inhibitor. J Am Chem Soc 111(15):5649–5658CrossRefGoogle Scholar
  37. 37.
    Tembre BL, Mc JA, Cammon (1984) Ligand-receptor interactions. Comput Chem 8(4):281–283CrossRefGoogle Scholar
  38. 38.
    Small-Molecule Drug Discovery Suite 2016-2, Schrödinger, LLC, New York, NY, 2016Google Scholar
  39. 39.
    Schrödinger Release 2016-2: Canvas, Schrödinger, LLC, New York, NY, 2016Google Scholar
  40. 40.
    Schrödinger Release 2016-2: LigPrep, Schrödinger, LLC, New York, NY, 2016Google Scholar
  41. 41.
    Schrödinger Release 2016-2: Schrödinger Suite 2016-2 Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2016; Impact, Schrödinger, LLC, New York, NY, 2016; Prime, Schrödinger, LLC, New York, NY, 2016Google Scholar
  42. 42.
    Sastry GM et al (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27(3):221–234CrossRefGoogle Scholar
  43. 43.
    Schrödinger Release 2016-2: WaterMap, Schrödinger, LLC, New York, NY, 2016Google Scholar
  44. 44.
    Abel R et al (2008) Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. J Am Chem Soc 130(9):2817–2831CrossRefGoogle Scholar
  45. 45.
    Young T et al (2007) Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc Natl Acad Sci USA 104(3):808–813CrossRefGoogle Scholar
  46. 46.
    Schrödinger Release 2016-2: Glide, Schrödinger, LLC, New York, NY, 2016Google Scholar
  47. 47.
    Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47(7):1739–1749CrossRefGoogle Scholar
  48. 48.
    Halgren TA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47(7):1750–1759CrossRefGoogle Scholar
  49. 49.
    Friesner RA et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49(21):6177–6196CrossRefGoogle Scholar
  50. 50.
    Schrödinger Release 2016-2: Phase, Schrödinger, LLC, New York, NY, 2016Google Scholar
  51. 51.
    Sastry GM, Dixon SL, Sherman W (2011) Rapid shape-based ligand alignment and virtual screening method based on atom/feature-pair similarities and volume overlap scoring. J Chem Inf Model 51(10):2455–2466CrossRefGoogle Scholar
  52. 52.
    Deng Z, Chuaqui C, Singh J (2004) Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. J Med Chem 47(2):337–344CrossRefGoogle Scholar
  53. 53.
    Singh J et al (2006) Structural interaction fingerprints: a new approach to organizing, mining, analyzing, and designing protein-small molecule complexes. Chem Biol Drug Des 67(1):5–12CrossRefGoogle Scholar
  54. 54.
    Dixon SL et al (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20(10–11):647–671CrossRefGoogle Scholar
  55. 55.
    Schrödinger Release 2016-2: Jaguar, Schrödinger, LLC, New York, NY, 2016Google Scholar
  56. 56.
    Bochevarov AD et al (2013) Jaguar: a high-performance quantum chemistry software program with strengths in life and materials sciences. Int J Quantum Chem 113(18):2110–2142CrossRefGoogle Scholar
  57. 57.
    Schrödinger Release 2016-2: Schrödinger Suite 2016-2 Induced Fit Docking protocol; Glide, Schrödinger, LLC, New York, NY, 2016; Prime, Schrödinger, LLC, New York, NY, 2016Google Scholar
  58. 58.
    Farid R et al (2006) New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg Med Chem 14(9):3160–3173CrossRefGoogle Scholar
  59. 59.
    Sherman W, Beard HS, Farid R (2006) Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des 67(1):83–84CrossRefGoogle Scholar
  60. 60.
    Sherman W et al (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49(2):534–553CrossRefGoogle Scholar
  61. 61.
    Clark AJ et al (2016) Prediction of protein-ligand binding poses via a combination of induced fit docking and metadynamics simulations. J Chem Theory Comput 12(6):2990–2998CrossRefGoogle Scholar
  62. 62.
    Sastry M et al (2010) Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments. J Chem Inf Model 50(5):771–784CrossRefGoogle Scholar
  63. 63.
    Zhou R, Das P, Royyuru AK (2008) Single mutation induced H3N2 hemagglutinin antibody neutralization: a free energy perturbation study. J Phys Chem B 112(49):15813–15820CrossRefGoogle Scholar
  64. 64.
    Kastenholz MA, Hunenberger PH (2006) Computation of methodology-independent ionic solvation free energies from molecular simulations. II. The hydration free energy of the sodium cation. J Chem Phys 124(22):224501CrossRefGoogle Scholar
  65. 65.
    Kastenholz MA, Hunenberger PH (2006) Computation of methodology-independent ionic solvation free energies from molecular simulations. I. The electrostatic potential in molecular liquids. J Chem Phys 124(12):124106CrossRefGoogle Scholar
  66. 66.
    Hummer G, Pratt LR, García AE (1996) Free energy of ionic hydration. J Phys Chem 100(4):1206–1215CrossRefGoogle Scholar
  67. 67.
    Kaus JW et al (2015) How to deal with multiple binding poses in alchemical relative protein-ligand binding free energy calculations. J Chem Theory Comput 11(6):2670–2679CrossRefGoogle Scholar
  68. 68.
    Liu S et al (2013) Lead optimization mapper: automating free energy calculations for lead optimization. J Comput Aided Mol Des 27(9):755–770CrossRefGoogle Scholar
  69. 69.
    Bennett CH (1976) Efficient estimation of free energy differences from Monte Carlo data. J Comput Phys 22(2):245–268CrossRefGoogle Scholar
  70. 70.
    Wang L et al (2013) Modeling local structural rearrangements using FEP/REST: application to relative binding affinity predictions of CDK2 inhibitors. J Chem Theory Comput 9(2):1282–1293CrossRefGoogle Scholar
  71. 71.
    Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(23):3099–3108CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Biomedical Research FoundationAcademy of AthensAthensGreece
  2. 2.Greek Research and Technology NetworkAthensGreece

Personalised recommendations